1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413

Awaiting development [GID-TA11488] Expected publication date: TBC

  • Project information
  • Project documents

NIHRIO BN: 30956-Tafasitamab-Lenalidomide-for-Follicular-or-Marginal-Zone-Lymphoma-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)